Federal Register / Vol. 66, No. 89 / Tuesday, May 8, 2001 / Notices 23263

analyze data that describes the current

problem and measures progress in

reducing commensal rodent infestation

and environmental hazards and

deficiencies in the target area.

2. Objectives (15 points)

The extent to which the applicant has

developed sound, feasible objectives

that are consistent with the activities

described in the project plan, and are

specific, measurable, and time-framed.

3. Project Plan (30 points)

a. The extent to which the applicant

provides evidence of its: (1) Ability to

collect and analyze target area data and

prepare reports of findings; (2) ability to

accurately assess intervention costs; and

(3) provide evidence of effective and

well-defined relationships within the

health department structure and with

other governmental components and

community-based organizations (CBOs)

to ensure identified environmental

hazards and deficiencies in the target

area are appropriately addressed.

b. The extent to which the project

plan takes into account all of the

elements of a comprehensive program

(see addendum).

c. The extent to which the applicant

describes the specific activities and

methods that are proposed to achieve

each of the program’s objectives. The

commitment of local resources to

sustain progress beyond expiration of

Federal funding also should be

addressed.

4. Coordination and Collaboration (15

points)

a. The extent to which the applicant

describes the relationship between the

health department program and other

health department components, other

government agencies, academia, and

CBOs and is supported by letters,

memoranda of agreement, and other

documented evidence in the appendix.

b. The extent to which the applicant

provides evidence of collaboration and

coordination between the health

department program and other health

department components, other

government agencies, academia, and

CBOs to achieve the objectives of the

project.

5. Project Management and Staffing (15

points)

a. The extent to which the applicant

documents skills and experience of key

health department staff, including staff

of collaborating agencies and

organizations to carry out

environmental public health programs,

and specifically, urban commensal

rodent control programs.

b. The extent to which the applicant

describes the allocation and roles of

staff and devotes time to the activities

described in the project plan.

6. Program Evaluation (10 points)

The extent to which the applicant

proposes to measure the overall impact

of project. The plan should describe the

methods used to evaluate the impact of

project activities on commensal rodent

infestation and environmental hazards

and deficiencies in the target area, and

on environmental public health

practices and polices.

7. Budget Justification (not scored)

The extent to which the budget is

clearly explained, adequately justified,

and is reasonable and consistent with

the stated objectives and planned

activities. Note: Please include any inkind support for the project.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with the original plus

two copies of:

1. Semi-annual progress reports

which are due within 30 days of the end

of each six-month reporting period;

2. The financial status report which is

due no more than 90 days after the end

of the budget period; and

3. The final financial and performance

reports which are due no more than 90

days after the end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

project. For a complete description of

each, see Attachment I in the

application kit.

AR–7 Executive Order 12372 Review

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

Sections 301 and 317 of the Public

Health Service Act, [42 U.S.C. Sections

241 and 247b]. The Catalog of Federal

Domestic Assistance number is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page

Internet address: http://www.cdc.gov by

clicking on ‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements.’’

To obtain additional information,

contact: Virginia Hall-Broadnax, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention, Mailstop E13—

2920 Brandywine Road, Suite 3000,

Atlanta, GA 30341–4146, Telephone

number: (770) 488–2710, E-mail

address: vdh2@cdc.gov.

For program technical assistance,

contact: Jerry M. Hershovitz, Assistant

to the Director for Program

Development, Division of Emergency

and Environmental Health Services,

National Center for Environmental

Health, Centers for Disease Control and

Prevention, Mailstop F–30—4770

Buford Highway, NE, Atlanta, Georgia

30341–2724, Telephone: (770) 488–

4542, E-mail: jmh6@cdc.gov.

Dated: May 2, 2001.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 01–11506 Filed 5–7–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Disease, Disability, and Injury

Prevention and Control Special

Emphasis Panel (SEP): Occupational

Exposure to Putative Reproductive/

Developmental Toxicants in Humans,

RFA OH–01–008

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. Law 92–463), the Centers for

Disease Control and Prevention (CDC)

announces the following meeting:

Name: Disease, Disability, and Injury

Prevention and Control Special Emphasis

Panel (SEP): Occupational Exposure to

Putative Reproductive/Developmental

Toxicants in Humans, RFA OH–01–008.

Times and Dates: 8 a.m.–8:30 a.m., May 30,

2001, (Open); 8:30 a.m.–5 p.m., May 30,

2001, (Closed); 8:30 a.m.–5 p.m., May 31,

2001, (Closed).

Place: Embassy Suites Hotel, 1900

Diagonal Road, Alexandria, VA 22314.

Status: Portions of the meeting will be

closed to the public in accordance with

provisions set forth in section 552b(c)(4) and

(6), Title 5 U.S.C., and the Determination of

the Deputy Director for Program

Management, CDC, pursuant to Public Law

92–463.

Matters To Be Discussed: The meeting will

include the review, discussion, and

evaluation of applications received in

23264 Federal Register / Vol. 66, No. 89 / Tuesday, May 8, 2001 / Notices

response to Program Announcement: RFA

OH–01–008.

Contact Person for More Information:

Pervis C. Major, PhD., Scientific Review

Administrator, National Institute for

Occupational Safety and Health, CDC, 1095

Willowdale Road, M/S B228, Morgantown,

West Virginia 26505, telephone 304–285–

5979.

The Director, Management Analysis and

Services Office has been delegated the

authority to sign Federal Register notices

pertaining to announcements of meetings and

other committee management activities, for

both the Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: April 20, 2001.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 01–11509 Filed 5–7–01; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1599]

Agency Information Collection

Activities; Announcement of OMB

Approval; Use of Impact-Resistant

Lenses in Eyeglasses and Sunglasses

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Use of Impact-Resistant Lenses in

Eyeglasses and Sunglasses’’ has been

approved by the Office of Management

and Budget (OMB) under the Paperwork

Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Peggy Schlosburg, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of March 7, 2001 (66

FR 13769), the agency announced that

the proposed information collection had

been submitted to OMB for review and

clearance under 44 U.S.C. 3507. An

agency may not conduct or sponsor, and

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. OMB has now approved the

information collection and has assigned

OMB control number 0910–0182. The

approval expires on April 30, 2004. A

copy of the supporting statement for this

information collection is available on

the Internet at http://www.fda.gov/

ohrms/dockets.

Dated: May 2, 2001.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 01–11451 Filed 5–7–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0393]

Agency Information Collection

Activities; Announcement of OMB

Approval; MedWatch: The FDA Medical

Products Reporting Program

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘MedWatch: The FDA Medical Products

Reporting Program’’ has been approved

by the Office of Management and

Budget (OMB) under the Paperwork

Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Mark L. Pincus, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1471.

SUPPLEMENTARY INFORMATION: In the

Federal Register of November 16, 2000

(65 FR 69314), the agency announced

that the proposed information collection

had been submitted to OMB for review

and clearance under 44 U.S.C. 3507. An

agency may not conduct or sponsor, and

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. OMB has now approved the

information collection and has assigned

OMB control number 0910–0291. The

approval expires on April 30, 2003. A

copy of the supporting statement for this

information collection is available on

the Internet at http://www.fda.gov/

ohrms/dockets.

Dated: May 2, 2001.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 01–11453 Filed 5–7–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1637]

Agency Information Collection

Activities; Submission for OMB

Review; Comment Request;

Transmittal of Advertising and

Promotional Labeling for Drugs and

Biologics for Human Use

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that the proposed collection of

information listed below has been

submitted to the Office of Management

and Budget (OMB) for review and

clearance under the Paperwork

Reduction Act of 1995.

DATES: Submit written comments on the

collection of information by June 7,

2001.

ADDRESSES: Submit written comments

on the collection of information to the

Office of Information and Regulatory

Affairs, OMB, New Executive Office

Bldg., 725 17th St. NW., rm. 10235,

Washington, DC 20503, Attn: Wendy

Taylor, Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1482.

SUPPLEMENTARY INFORMATION: In

compliance with 44 U.S.C. 3507, FDA

has submitted the following proposed

collection of information to OMB for

review and clearance.

Transmittal of Advertising and

Promotional Labeling for Drugs and

Biologics for Human Use

Under § 314.81(b)(3)(i) (21 CFR

314.81(b)(3)(i), sponsors of approved

applications for marketed prescription

drugs and antibiotic drugs for human

use are required to submit specimens of

promotional labeling and

advertisements at the time of initial

dissemination of the labeling and at the

time of initial publication of the

advertisements. Each submission is

required to be accompanied by a

completed transmittal Form FDA 2253

(Transmittal of Advertisements and

Promotional Labeling for Drugs and

Biologics for Human Use). Statutory

authority for the collection of this

information is provided by sections

505(a), (b), (j), and (k) and 701(a) of the